Michael J Milazzo, DO in Bisbee, AZ - General Practice

Michael J Milazzo, DO is a General Practice physician based in Bisbee, Arizona. Michael J Milazzo is licensed to practice in Arizona (license number 1887) and his current practice location is 108 Arizona St, Bisbee, Arizona. He can be reached at his office (for appointments etc.) via phone at (520) 432-3309.

NPI number for Michael J Milazzo is 1548593510 and his current mailing address is 1205 F Ave, Douglas, Arizona. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1548593510.

Contact Information

	Michael J Milazzo, DO
	108 Arizona St, Bisbee, AZ 85603-1804
	(520) 432-3309
	(520) 364-4261

Physician's Profile

Full Name	Michael J Milazzo
Gender	Male
Speciality	General Practice
Location	108 Arizona St, Bisbee, Arizona
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1548593510
Provider Enumeration Date: 09/09/2009
Last Update Date: 06/12/2013

Medical Identifiers

Medical identifiers for Michael J Milazzo such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1548593510	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208D00000X	General Practice	1887 (Arizona)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Michael J Milazzo is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Michael J Milazzo, DO 1205 F Ave, Douglas, AZ 85607-1920 Ph: (520) 364-1429	Michael J Milazzo, DO 108 Arizona St, Bisbee, AZ 85603-1804 Ph: (520) 432-3309

News Archive

LMU researchers identify microRNA that offers promising target for new therapies

Atherosclerosis, an inflammatory reaction, is at the root of the most common forms of cardiovascular disease. Researchers at Ludwig-Maximilians-Universitaet in Munich have now identified a microRNA that plays a prominent role in the process, and offers a promising target for new therapies.

SLU Hospital's CEO honored with Patriot Award

Crystal L. Haynes, Chief Executive Officer at Saint Louis University Hospital, will be honored as a recipient of a Patriot Award from the Employee Support of the Guard and Reserve (ESGR), a staff organization within the U.S. Department of Defense. The

Blood pressure treatment may prevent end-stage kidney disease in some patients: Study

Intensively treating hypertension in some African Americans with kidney disease by pushing blood pressure well below the current recommended goal may significantly decrease the number who lose kidney function and require dialysis, suggests a Johns Hopkins-led study publishing in the New England Journal of Medicine Thursday.

German life sciences entrepreneurs granted option to develop Aeterna Zentaris' oral allogenic tumor vaccine technology

Aeterna Zentaris Inc. today announced that it has granted to German life sciences entrepreneurs with a proven track-record of funding the development and commercialization of biotechnology, an option to license the Company's live recombinant oral allogenic tumor vaccine technology, including AEZS-120, the most advanced product candidate for prostate cancer which is ready to enter a Phase 1 clinical trial.

Michael J Milazzo, DO - General Practice in Bisbee, AZ